Information  X 
Enter a valid email address

Onzima Ventures PLC (ONZ)

  Print   

Tuesday 02 May, 2017

Onzima Ventures PLC

Result of General Meeting

RNS Number : 9241D
Onzima Ventures PLC
02 May 2017
 

02 May 2017

Onzima Ventures plc (to be re-named N4 Pharma Plc)

(the "Company")

Result of General Meeting, Directorate Changes, Share Re-organisation, Change of Name and Website address and Voting Rights

Result of General Meeting

The Company is pleased to announce that all resolutions put to Shareholders at the General Meeting held earlier today were duly passed and therefore completion of the acquisition of N4 Pharma Limited is expected to take place on 3 May 2017.

Directorate Changes

Following the passing of the resolutions as set out above, the Company announces, each with effect upon Admission, the resignations of Gavin Burnell, Chief Executive, and Professor Humayun Mughal, Non-Executive Director, as directors of the Company and the appointments of David Templeton, Non-Executive Chairman, Nigel Theobald, Chief Executive, and Paul Titley, Executive Director, as directors of the Company. Further details on the newly appointed directors are set out in the Appendix below.

Share Re-organisation

At the General Meeting, Shareholders approved the Share Re-organisation which is expected to take place after close of business on the Record Date, being 2 May 2017. Fractional entitlements resulting from the Share Re-organisation will be sold for the benefit of Shareholders other than amounts of less than £5.00 which the Company will retain for its own benefit.

Change of Name and Website Address

At the General Meeting, Shareholders also approved the change of the Company's name from Onzima Ventures Plc to N4 Pharma Plc. The change of name will be effective once Companies House has issued a certificate of incorporation on change of name which is expected to occur by Admission. The Company's AIM symbol will change to N4P with effect from 8.00am on 3 May 2017. 

Following the change of the Company's name becoming effective, its website address, which will include the information required by AIM Rule 26, will be www.n4pharma.com.

Voting Rights

Application has been made for the Enlarged Share Capital to be admitted to trading on AIM. It is expected that restoration of trading on AIM in the Existing Ordinary Shares and Admission will become effective and that dealings in the Enlarged Share Capital will commence at 8.00am on 3 May 2017.

Following completion of the Company's Share Re-organisation and Admission, the Enlarged Share Capital will comprise 71,714,285 Ordinary Shares. Each Ordinary Share has one voting right.  No Ordinary Shares are held in treasury.  Accordingly, the total number of voting rights will be 71,714,285.

The above figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, N4 Pharma plc under the FCA's Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement shall have the same meaning as in the Company's admission document published on 13 April 2017, copies of which are available on the Company's website. 

Enquiries:

N4 Pharma

Nigel Theobald, CEO

 

Via Alma PR

Stockdale Securities

Tom Griffiths

 

Tel: +44(0)207 601 6100

Beaufort Securities
Elliot Hance


Tel: +44(0)207 382 8300

Alma PR

Josh Royston

Robyn Fisher

 

Tel: +44(0)778 090 1979

Tel: +44(0)754 070 6191

 

Appendix

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. The newly appointed Directors, as mentioned above, hold or have held the following directorships or have been partners in the following partnerships within the past five years:

 

Name

Current Directorships/Partnerships

Past Directorships/Partnerships

David Templeton

None

DT Pharmacology Consultancy Limited

 

Nigel Theobald

Askalane Limited

Lytegro Limited

Medherant Limited

N4 Pharma Limited

Oxford Nutra Limited

Oxford Pharmascience Group Plc

Oxford Pharmascience Limited 

 

Paul Titley

Critical Pharmaceuticals Limited

Keswick Community Asset Company

Keswick Museum and Art Gallery

N4 Pharma Limited

 

Aesica Formulation Development

 

In addition, as at the date of this announcement, Nigel Theobald holds 29,893,963 Existing Ordinary Shares, representing approximately 16.1 per cent of the Existing Ordinary Share Capital.

There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) of the AIM Rules for Companies.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMLLFIVEFIFIID

a d v e r t i s e m e n t